Advanced liver cancer Pipeline Insight, 2020

 Breaking News
  • No posts were found

Advanced liver cancer Pipeline Insight, 2020

April 21
12:24 2020
Advanced liver cancer Pipeline Insight, 2020

DelveInsight has launched a new report on Advanced liver cancer Pipeline Insight, 2020

Advanced liver cancer Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Advanced liver cancer market. A detailed picture of the Advanced liver cancer pipeline landscape is provided, which includes the disease overview and Advanced liver cancer treatment guidelines. The assessment part of the report embraces in-depth Advanced liver cancer commercial assessment and clinical assessment of the Advanced liver cancer pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced liver cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Advanced Liver Cancer is a stage IV Liver Cancer in which the cancer has spread to nearby lymph nodes and may have grown into nearby blood vessels or organs. It does not often metastasize but when it does, it is most likely to spread to the lungs and bones. It is further categorized into IVA and IVB stages. In stage IVA the cancer have grown into blood vessels or the organs around the liver and has spread to lymph nodes but not to other parts of the body. While in stage IVB the cancer spread to another part of the body such as the lungs or bones.


Request for free sample page

 Pipeline Development Activities 

The report provides insights into: 

  • All of the companies that are developing therapies for the treatment of Advanced liver cancer with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Advanced liver cancer treatment.
  • Advanced liver cancer key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Advanced liver cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Report key facts:- 

1. According to Japanese Journal of Clinical Oncology, the proportion of early-stage Hepatocellular Carcinoma (HCC) is about 65%, whereas only 5% patients are present with advanced-stage in Japan.

2. According to Cancer Research UK, Incidence rates are significantly higher in males than females in a number of (mainly older) age groups .

3. According to Centers for Disease Control and Prevention,  estimates that, about 33,000 people get liver cancer, and about 26,000 people die from the disease each year in the United States

Some of key major companies are working on this disease which are given below:- 

1. Ono Pharmaceutical Co. Ltd 

2. Benhealth Biopharmaceutical Co., Ltd

3. Millennium Pharmaceutical Co. Ltd

Name of drugs covered which are given below:- 

1. Nivolumab

2. CIK and CD3-MUC1

3. MLN0128 

Table of content

1. Report Introduction

2. Advanced liver cancer 

3. Advanced liver cancer Current Treatment Patterns

4. Advanced liver cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Advanced liver cancer Late Stage Products (Phase-III)

7. Advanced liver cancer Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Advanced liver cancer Discontinued Products

13. Advanced liver cancer Product Profiles

14. Advanced liver cancer Key Companies

15. Advanced liver cancer Key Products

16. Dormant and Discontinued Products

17. Advanced liver cancer Unmet Needs

18. Advanced liver cancer Future Perspectives

19. Advanced liver cancer Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

22. About Delveinsight

Related Reports:- 

1. Advanced Heart Failure – Pipeline Insights, 2020

2. Advanced Pancreatic Cancer – Pipeline Insights, 2020

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles